The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
05-Apr-24
Pending
$820 million (AUD)
Target:
illion Australia Pty Ltd
Acquiror:
Experian Plc
Advising Experian Plc, the world’s leading global information services company, on the acquisition of illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
07-Dec-21
$153 million
Target:
Japan Medical Dynamic Marketing
Acquiror:
Mitsui Chemicals
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
01-Nov-21
$400 million
Target:
Millennial Lithium
Acquiror:
Lithium Americas
Advised Lithium Americas, a development-stage company with projects in Jujuy, Argentina and Nevada, United States on its acquisition of Millennial Lithium, a Vancouver-based exploration and development company focused on advancing the Pastos Grandes Lithium Project in Argentina
14-Jul-21
Undisclosed
Target:
New Day Aluminum LLC
Acquiror:
Concord Resources Ltd.
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
27-May-21
$1.4 billion
Target:
Equiniti Group PLC
Acquiror:
Siris Capital Group LLC
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
10-Sep-20
$195 million
Target:
Saga plc
Acquiror:
Sir Roger De Haan
Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$134 million
Target:
Equity stake in Bupa Arabia
Acquiror:
Bupa Ltd.
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
18-Mar-20
$NA
Target:
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
Acquiror:
Eppendorf AG
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
02-Mar-20
$NA
Target:
Global rights (excluding North America) to ThermaCare (United Kingdom)
Acquiror:
Angelini Pharma
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
20-Feb-20
$NA
Target:
Asia and US rights to Physiogel
Acquiror:
LG Household & Health Care
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
28-Oct-19
$NA
Target:
Supplier Participações
Acquiror:
Totvs
Advised Supplier Participações, the largest credit fintech company in Brazil and the first independent mover in supply chain financing, on the sale of a majority stake to Totvs, the leading provider of management software and related consulting services in Brazil
23-Aug-19
$NA
Target:
TT International
Acquiror:
Sumitomo Mitsui Financial Group, Inc.
Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.
19-Jul-19
$NA
Target:
Ourinvest DTVM
Acquiror:
BTG Pactual
Advised the shareholders of Ourinvest DTVM, a leading Brazilian securities broker focused on providing high net-worth individuals custody, distribution and trading services, on the sale of an 80% stake to BTG Pactual, one of Brazil’s largest independent investment banking firms